The drug targets both the neurological and inflammatory triggers of migraines
Cadila Pharmaceuticals has launched Vasograin Plus, a novel, dual-action formulation designed for the acute treatment of migraines with or without aura in both adults and adolescents.
Vasograin Plus represents a major advancement in the treatment of migraine, a condition that affects millions globally and significantly influences quality of life. It is a unique therapy that combines two well-established pharmacological agents to work through complementary mechanisms, targeting both the neurological and inflammatory triggers of migraines.
Dr Rajiv I Modi, CMD, Cadila Pharmaceuticals, said, “At Cadila Pharmaceuticals, we believe healthcare should not just treat, but empower. Vasograin Plus is the result of rigorous science, patient needs, and our unwavering focus on innovation. With its launch, we reaffirm our commitment to helping people live healthier, fuller lives, free from the limitations imposed by chronic conditions like migraine.”
